SIRT3表观遗传学和心力衰竭病理变化的研究进展
Progress in SIRT3 Epigenetics and Pathological Changes in Heart Failure
DOI: 10.12677/md.2024.143038, PDF,    科研立项经费支持
作者: 张克坚：济宁医学院临床医学院，山东 济宁；王青雷*：济宁医学院附属医院CCU，山东 济宁
关键词: SIRT3；心力衰竭；表观遗传学；去乙酰化；SIRT3； Heart Failure； Epigenetics； Eacetylation
摘要: 心力衰竭是各种心脏疾病的终末阶段，其病理过程贯穿发病的各个环节。SIRT3是SIRTUIN家族的重要一员，属于烟酰胺腺嘌呤二核苷酸(NAD+)依赖性脱乙酰酶的Sirtuin家族，亚细胞主要定位于线粒体，在心脏中高度表达。表观遗传学不牵涉DNA的序列变化，而基因组相关功能改变，比如组蛋乙酰化相关的SIRT3可通过各种通路及调节因子，对心肌纤维化、心肌肥厚、心肌凋亡等病理过程进行调节，对心力衰竭的发生、发展产生重要影响。本文主要综述SIRT3在心力衰竭各病理过程中的研究进展。
Abstract: Heart failure is the terminal stage of various heart diseases, and its pathological process runs through every link of the disease. SIRT3 is an important member of the Sirtuin family, belonging to the sirtuin family of nicotinamide adenine dinucleotide (NAD+)-dependent deacetylases, which is subcellular localized in mitochondria and is highly expressed in the heart. Epigenetics does not involve the sequence changes of DNA, but genome-related functional changes, such as egg acetylation- related SIRT3, can regulate myocardial fibrosis, myocardial hypertrophy, myocardial apoptosis and other pathological processes through various pathways and regulatory factors, and have an important impact on the occurrence and development of heart failure. This paper mainly reviews the progress of SIRT3 in each pathological process of heart failure.
文章引用：张克坚, 王青雷. SIRT3表观遗传学和心力衰竭病理变化的研究进展[J]. 医学诊断, 2024, 14(3): 256-264. https://doi.org/10.12677/md.2024.143038

参考文献

[1] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志, 2014, 42(2): 98-122.
[2] 吴伟东, 易永盛, 周洋洋. microRNA在心力衰竭病理变化过程中的调节意义[J]. 心血管病学进展, 2016(5): 554-558.
[3] Lu, Y., Wang, Y., Wang, X., Chen, H., Cai, Z. and Xiang, M. (2016) SIRT3 in Cardiovascular Diseases: Emerging Roles and Therapeutic Implications. International Journal of Cardiology, 220, 700-705. [Google Scholar] [CrossRef] [PubMed]
[4] Dai, L., Xie, Y., Zhang, W., Zhong, X., Wang, M., Jiang, H., et al. (2021) Weighted Gene Co-Expression Network Analysis Identifies ANGPTL4 as a Key Regulator in Diabetic Cardiomyopathy via FAK/SIRT3/ROS Pathway in Cardiomyocyte. Frontiers in Endocrinology, 12, Article 705154. [Google Scholar] [CrossRef] [PubMed]
[5] Zhang, D., Zhang, C., Fu, B., Sun, L., Wang, X., Chen, W., et al. (2018) Sirtuin3 Protects Aged Human Mesenchymal Stem Cells against Oxidative Stress and Enhances Efficacy of Cell Therapy for Ischaemic Heart Diseases. Journal of Cellular and Molecular Medicine, 22, 5504-5517. [Google Scholar] [CrossRef] [PubMed]
[6] Chen, Y., Chen, C., Dong, B., Xing, F., Huang, H., Yao, F., et al. (2017) AMPK Attenuates Ventricular Remodeling and Dysfunction Following Aortic Banding in Mice via the Sirt3/oxidative Stress Pathway. European Journal of Pharmacology, 814, 335-342. [Google Scholar] [CrossRef] [PubMed]
[7] Fu, M., Liu, M., Sauve, A.A., Jiao, X., Zhang, X., Wu, X., et al. (2006) Hormonal Control of Androgen Receptor Function through Sirt1. Molecular and Cellular Biology, 26, 8122-8135. [Google Scholar] [CrossRef] [PubMed]
[8] Zhang, J., Xiang, H., Liu, J., Chen, Y., He, R. and Liu, B. (2020) Mitochondrial Sirtuin 3: New Emerging Biological Function and Therapeutic Target. Theranostics, 10, 8315-8342. [Google Scholar] [CrossRef] [PubMed]
[9] Onyango, P., Celic, I., McCaffery, J.M., Boeke, J.D. and Feinberg, A.P. (2002) SIRT3, a Human SIR2 Homologue, Is an NAD-Dependent Deacetylase Localized to Mitochondria. Proceedings of the National Academy of Sciences, 99, 13653-13658. [Google Scholar] [CrossRef] [PubMed]
[10] Schwer, B., North, B.J., Frye, R.A., Ott, M. and Verdin, E. (2002) The Human Silent Information Regulator (sir)2 Homologue Hsirt3 Is a Mitochondrial Nicotinamide Adenine Dinucleotide-Dependent Deacetylase. The Journal of Cell Biology, 158, 647-657. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, X., Ameer, F.S., Azhar, G. and Wei, J.Y. (2021) Alternative Splicing Increases Sirtuin Gene Family Diversity and Modulates Their Subcellular Localization and Function. International Journal of Molecular Sciences, 22, Article 473. [Google Scholar] [CrossRef] [PubMed]
[12] Paku, M., Haraguchi, N., Takeda, M., Fujino, S., Ogino, T., Takahashi, H., et al. (2021) Sirt3-Mediated SOD2 and Pgc-1α Contribute to Chemoresistance in Colorectal Cancer Cells. Annals of Surgical Oncology, 28, 4720-4732. [Google Scholar] [CrossRef] [PubMed]
[13] Mihanfar, A., Nejabati, H.R., Fattahi, A., latifi, Z., Faridvand, Y., Pezeshkian, M., et al. (2018) Sirt3-Mediated Cardiac Remodeling/Repair Following Myocardial Infarction. Biomedicine & Pharmacotherapy, 108, 367-373. [Google Scholar] [CrossRef] [PubMed]
[14] Li, M., Li, C., Ye, Z., Huang, J., Li, Y., Lai, W., et al. (2020) Sirt3 Modulates Fatty Acid Oxidation and Attenuates Cisplatin-Induced AKI in Mice. Journal of Cellular and Molecular Medicine, 24, 5109-5121. [Google Scholar] [CrossRef] [PubMed]
[15] Barroso, E., Rodríguez-Rodríguez, R., Zarei, M., Pizarro-Degado, J., Planavila, A., Palomer, X., et al. (2020) SIRT3 Deficiency Exacerbates Fatty Liver by Attenuating the HIF1α-LIPIN 1 Pathway and Increasing CD36 through Nrf2. Cell Communication and Signaling, 18, Article No. 147. [Google Scholar] [CrossRef] [PubMed]
[16] Anamika Khanna, A., Acharjee, P., Acharjee, A. and Trigun, S.K. (2019) Mitochondrial SIRT3 and Neurodegenerative Brain Disorders. Journal of Chemical Neuroanatomy, 95, 43-53. [Google Scholar] [CrossRef] [PubMed]
[17] Sopic, M., Robinson, E.L., Emanueli, C., Srivastava, P., Angione, C., Gaetano, C., et al. (2023) Integration of Epigenetic Regulatory Mechanisms in Heart Failure. Basic Research in Cardiology, 118, Article No. 16. [Google Scholar] [CrossRef] [PubMed]
[18] Stillman, B. (2018) Histone Modifications: Insights into Their Influence on Gene Expression. Cell, 175, 6-9. [Google Scholar] [CrossRef] [PubMed]
[19] Strahl, B.D. and Allis, C.D. (2000) The Language of Covalent Histone Modifications. Nature, 403, 41-45. [Google Scholar] [CrossRef] [PubMed]
[20] Koser, F., Hobbach, A.J., Abdellatif, M., Herbst, V., Türk, C., Reinecke, H., et al. (2022) Acetylation and Phosphorylation Changes to Cardiac Proteins in Experimental HfpEF Due to Metabolic Risk Reveal Targets for Treatment. Life Sciences, 309, Article 120998. [Google Scholar] [CrossRef] [PubMed]
[21] de Loof, M., Renguet, E., Ginion, A., Bouzin, C., Horman, S., Beauloye, C., et al. (2023) Enhanced Protein Acetylation Initiates Fatty Acid-Mediated Inhibition of Cardiac Glucose Transport. American Journal of Physiology-Heart and Circulatory Physiology, 324, H305-H317. [Google Scholar] [CrossRef] [PubMed]
[22] Chelladurai, P., Boucherat, O., Stenmark, K., Kracht, M., Seeger, W., Bauer, U. M., Bonnet,Chelladurai, P., Boucherat, O., Stenmark, K., Kracht, M., Seeger, W., Bauer, U., et al. (2020) Targeting Histone Acetylation in Pulmonary Hypertension and Right Ventricular Hypertrophy. British Journal of Pharmacology, 178, 54-71. [Google Scholar] [CrossRef] [PubMed]
[23] Qin, J., Guo, N., Tong, J. and Wang, Z. (2021) Function of Histone Methylation and Acetylation Modifiers in Cardiac Hypertrophy. Journal of Molecular and Cellular Cardiology, 159, 120-129. [Google Scholar] [CrossRef] [PubMed]
[24] Scott, I. and Sack, M.N. (2020) Rethinking Protein Acetylation in Pressure Overload-Induced Heart Failure. Circulation Research, 127, 1109-1111. [Google Scholar] [CrossRef] [PubMed]
[25] Yu, Q., Zhao, G., Liu, J., Peng, Y., Xu, X., Zhao, F., et al. (2023) The Role of Histone Deacetylases in Cardiac Energy Metabolism in Heart Diseases. Metabolism, 142, Article 155532. [Google Scholar] [CrossRef] [PubMed]
[26] Chan, D.C. (2020) Mitochondrial Dynamics and Its Involvement in Disease. Annual Review of Pathology: Mechanisms of Disease, 15, 235-259. [Google Scholar] [CrossRef] [PubMed]
[27] van der Bliek, A.M., Shen, Q. and Kawajiri, S. (2013) Mechanisms of Mitochondrial Fission and Fusion. Cold Spring Harbor Perspectives in Biology, 5, a011072. [Google Scholar] [CrossRef] [PubMed]
[28] Hu, J., Liu, T., Fu, F., Cui, Z., Lai, Q., Zhang, Y., et al. (2022) Omentin1 Ameliorates Myocardial Ischemia-Induced Heart Failure via SIRT3/FOXO3a-Dependent Mitochondrial Dynamical Homeostasis and Mitophagy. Journal of Translational Medicine, 20, Article No. 447. [Google Scholar] [CrossRef] [PubMed]
[29] Nan, J., Hu, H., Sun, Y., Zhu, L., Wang, Y., Zhong, Z., et al. (2017) TNFR2 Stimulation Promotes Mitochondrial Fusion via Stat3-and NF-kB-Dependent Activation of OPA1 Expression. Circulation Research, 121, 392-410. [Google Scholar] [CrossRef] [PubMed]
[30] 胡伯昂. SIRT3基因在慢性心力衰竭患者中的表达及其与氧化应激的相关性研究[D]: [硕士学位论文]. 济南: 山东大学, 2019.
[31] Li, H. and Cai, Z. (2023) SIRT3 Regulates Mitochondrial Biogenesis in Aging-Related Diseases. The Journal of Biomedical Research, 37, 77-88. [Google Scholar] [CrossRef] [PubMed]
[32] Samant, S.A., Zhang, H.J., Hong, Z., Pillai, V.B., Sundaresan, N.R., Wolfgeher, D., et al. (2014) SIRT3 Deacetylates and Activates OPA1 to Regulate Mitochondrial Dynamics during Stress. Molecular and Cellular Biology, 34, 807-819. [Google Scholar] [CrossRef] [PubMed]
[33] Liu, J., Yan, W., Zhao, X., Jia, Q., Wang, J., Zhang, H., Liu, C., He, K. and Sun, Z. (2019) Sirt3 Attenuates Post-Infarction Cardiac Injury via Inhibiting Mitochondrial Fission and Normalization of Ampk-Drp1 Pathways. Cellular Signalling, 53, 1-13. [Google Scholar] [CrossRef] [PubMed]
[34] Geng, Z., Chen, W., Lu, Q., Fu, B. and Fu, X. (2024) UCP2 Overexpression Activates SIRT3 to Regulate Oxidative Stress and Mitochondrial Dynamics Induced by Myocardial Injury. Archives of Biochemistry and Biophysics, 753, Article 109918. [Google Scholar] [CrossRef] [PubMed]
[35] Tsutsui, H., Kinugawa, S. and Matsushima, S. (2008) Mitochondrial Oxidative Stress and Dysfunction in Myocardial Remodelling. Cardiovascular Research, 81, 449-456. [Google Scholar] [CrossRef] [PubMed]
[36] Pagan, L.U., Gomes, M.J., Martinez, P.F. and Okoshi, M.P. (2022) Oxidative Stress and Heart Failure: Mechanisms, Signalling Pathways, and Therapeutics. Oxidative Medicine and Cellular Longevity, 2022, 1-3. [Google Scholar] [CrossRef] [PubMed]
[37] Peng, S., Lu, X., Qi, Y., Li, J., Xu, J., Yuan, T., et al. (2020) LCZ696 Ameliorates Oxidative Stress and Pressure Overload-Induced Pathological Cardiac Remodeling by Regulating the Sirt3/MnSOD Pathway. Oxidative Medicine and Cellular Longevity, 2020, 1-15. [Google Scholar] [CrossRef] [PubMed]
[38] Chen, Y., Luo, H., Sun, L., Xu, M., Yu, J., Liu, L., et al. (2018) Dihydromyricetin Attenuates Myocardial Hypertrophy Induced by Transverse Aortic Constriction via Oxidative Stress Inhibition and SIRT3 Pathway Enhancement. International Journal of Molecular Sciences, 19, Article 2592. [Google Scholar] [CrossRef] [PubMed]
[39] Chang, G., Chen, Y., Zhang, H. and Zhou, W. (2019) Trans Sodium Crocetinate Alleviates Ischemia/reperfusion-Induced Myocardial Oxidative Stress and Apoptosis via the SIRT3/FOXO3a/SOD2 Signaling Pathway. International Immunopharmacology, 71, 361-371. [Google Scholar] [CrossRef] [PubMed]
[40] 郑婧婧, 卜宁, 赵钊, 等. 心肌肥大表观遗传调控的研究进展[J]. 基础医学与临床, 2022(3): 520-524.
[41] Ding, Y., Zhang, Y., Lu, J., Li, B., Yu, W., Yue, Z., et al. (2020) Microrna-214 Contributes to Ang II-Induced Cardiac Hypertrophy by Targeting SIRT3 to Provoke Mitochondrial Malfunction. Acta Pharmacologica Sinica, 42, 1422-1436. [Google Scholar] [CrossRef] [PubMed]
[42] Li, Z., Lu, G., Lu, J., Wang, P., Zhang, X., Zou, Y., et al. (2022) SZC-6, a Small-Molecule Activator of SIRT3, Attenuates Cardiac Hypertrophy in Mice. Acta Pharmacologica Sinica, 44, 546-560. [Google Scholar] [CrossRef] [PubMed]
[43] Li, Z., Hu, O., Xu, S., Lin, C., Yu, W., Ma, D., et al. (2024) The SIRT3-ATAD3A Axis Regulates MAM Dynamics and Mitochondrial Calcium Homeostasis in Cardiac Hypertrophy. International Journal of Biological Sciences, 20, 831-847. [Google Scholar] [CrossRef] [PubMed]
[44] Feng, X., Wang, Y., Chen, W., Xu, S., Li, L., Geng, Y., et al. (2020) SIRT3 Inhibits Cardiac Hypertrophy by Regulating PARP-1 Activity. Aging, 12, 4178-4192. [Google Scholar] [CrossRef] [PubMed]
[45] Wang, M., Ding, Y., Hu, Y., Li, Z., Luo, W., Liu, P., et al. (2023) SIRT3 Improved Peroxisomes-Mitochondria Interplay and Prevented Cardiac Hypertrophy via Preserving PEX5 Expression. Redox Biology, 62, Article 102652. [Google Scholar] [CrossRef] [PubMed]
[46] Soliman, H. and Rossi, F.M.V. (2020) Cardiac Fibroblast Diversity in Health and Disease. Matrix Biology, 91, 75-91. [Google Scholar] [CrossRef] [PubMed]
[47] 易胜利, 邓玮. 心肌纤维化发病机制研究进展[J]. 现代医药生, 2022, 38(12): 2051-2055.
[48] Su, H., Zeng, H., Liu, B. and Chen, J. (2020) Sirtuin 3 Is Essential for Hypertension-Induced Cardiac Fibrosis via Mediating Pericyte Transition. Journal of Cellular and Molecular Medicine, 24, 8057-8068. [Google Scholar] [CrossRef] [PubMed]
[49] Su, H., Cantrell, A.C., Chen, J., Gu, W. and Zeng, H. (2023) SIRT3 Deficiency Enhances Ferroptosis and Promotes Cardiac Fibrosis via P53 Acetylation. Cells, 12, Article 1428. [Google Scholar] [CrossRef] [PubMed]
[50] Palomer, X., Román-Azcona, M.S., Pizarro-Delgado, J., Planavila, A., Villarroya, F., Valenzuela-Alcaraz, B., et al. (2020) Sirt3-Mediated Inhibition of FOS through Histone H3 Deacetylation Prevents Cardiac Fibrosis and Inflammation. Signal Transduction and Targeted Therapy, 5, Article No. 14. [Google Scholar] [CrossRef] [PubMed]
[51] 雷雨, 任静, 付蓉, 等. 心力衰竭与心肌细胞凋亡及中医药研究进展[J]. 中医药临床杂志, 2021(9): 1834-1837.
[52] Zhai, M., Li, B., Duan, W., Jing, L., Zhang, B., Zhang, M., et al. (2017) Melatonin Ameliorates Myocardial Ischemia Reperfusion Injury through Sirt3-Dependent Regulation of Oxidative Stress and Apoptosis. Journal of Pineal Research, 63, e12419. [Google Scholar] [CrossRef] [PubMed]
[53] Adam, L.N., Al-Habib, O.A.M. and Shekha, M.S. (2023) Exploring the Role of Sirtuin 3 Gene Polymorphisms and Oxidative Stress Markers in the Susceptibility to Coronary Artery Disease. Molecular Biology Reports, 50, 9221-9228. [Google Scholar] [CrossRef] [PubMed]
[54] Song, X., Wang, H., Wang, C., Ji, G., Jiang, P., Liang, D., et al. (2022) Association of Sirtuin Gene Polymorphisms with Susceptibility to Coronary Artery Disease in a North Chinese Population. BioMed Research International, 2022, 1-8. [Google Scholar] [CrossRef] [PubMed]
[55] 朱林. SIRT3基因多态性与老年慢性心衰相关性的初步临床研究[D]: [硕士学位论文]. 济南: 山东大学, 2017.